Le Lézard
Classified in: Health
Subject: TRD

Chardan Healthcare Acquisition Corp. Securities To Commence Separate Trading


NEW YORK, March 12, 2019 /PRNewswire/ -- Chardan Healthcare Acquisition Corp. (NYSE American: CHAC.U) (the "Company") announced today that separate trading of its common stock and warrants underlying the Company's units would commence on or about March 13, 2019. The common stock and warrants will trade under the symbols "CHAC" and "CHAC.W", respectively. Units not separated will continue to be listed on NYSE American under the symbol "CHAC.U."

Chardan Healthcare Acquisition Corp. is a blank check company organized for the purpose of effecting a business combination with one or more target businesses. Chardan Healthcare Acquisition Corp.'s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although it intends to focus its search on target businesses operating in North America in the healthcare industry.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws.  These forward-looking statements inherently involve risks and uncertainties that are detailed in the companies' registration statements and other filings with the Securities and Exchange Commission and, therefore, actual results could differ materially from those projected in the forward-looking statements.  The companies assume no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company:

Chardan Healthcare Acquisition Corp.
Jonas Grossman, CEO
17 State Street, 21st Floor, New York, NY 10004
(646) 465-9002

SOURCE Chardan Healthcare Acquisition Corp.


These press releases may also interest you

at 02:43
Immunovia Publishes Interim Report for January-March 2024
January-March 2024 Net sales, which for the quarter only included royalties, amounted to SEK 156 (520)Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact.Earnings per share before...

at 02:27
Global Biometric Technologies Market Share, Trends, Size, Players, Statics, Facts, Opportunity & Forecast (2024-2031) | Pheonix Research
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Locate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 01:00
Philips delivers first-quarter results in line with 2024 performance improvement plan; Resolves the Respironics personal injury and medical monitoring litigation in the US for USD 1.1 billion
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma Announces Total Capital of ?15 Million Successfully Secured in Second Closing
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

More news about Health...


News published on and distributed by: